Pink SheetAIM-NASH, the first artificial intelligence (AI)-based pathology tool to be qualified by the European Medicines Agency for assessing drug candidates for metabolic dysfunction-associated steatohepatiti
ScripAfter overcoming a financial shortfall in 2024, Inventiva is cutting staff by 50% and ceasing its preclinical research and development efforts to try to make its money last long enough to get Phase II
ScripThird Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut
ScripMany of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first